Dai ichi Life Insurance Company Ltd Trims Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Dai ichi Life Insurance Company Ltd lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 13.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,119 shares of the company’s stock after selling 6,358 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Neurocrine Biosciences were worth $4,853,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Qsemble Capital Management LP purchased a new position in shares of Neurocrine Biosciences during the third quarter valued at about $1,238,000. Bank of Montreal Can grew its holdings in Neurocrine Biosciences by 40.4% in the third quarter. Bank of Montreal Can now owns 55,244 shares of the company’s stock worth $6,356,000 after purchasing an additional 15,893 shares during the period. Truvestments Capital LLC purchased a new stake in Neurocrine Biosciences in the third quarter worth about $63,000. Fisher Asset Management LLC grew its holdings in Neurocrine Biosciences by 7.8% in the third quarter. Fisher Asset Management LLC now owns 68,270 shares of the company’s stock worth $7,866,000 after purchasing an additional 4,930 shares during the period. Finally, Daiwa Securities Group Inc. grew its holdings in Neurocrine Biosciences by 34.1% in the third quarter. Daiwa Securities Group Inc. now owns 11,798 shares of the company’s stock worth $1,360,000 after purchasing an additional 2,997 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

NBIX has been the topic of a number of recent research reports. Citigroup upped their price objective on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Piper Sandler upgraded shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $131.00 to $159.00 in a report on Thursday, August 29th. BMO Capital Markets cut their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a report on Thursday, October 17th. Robert W. Baird increased their price target on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Finally, HC Wainwright reiterated a “buy” rating and set a $190.00 price target on shares of Neurocrine Biosciences in a report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Trading Up 0.6 %

Neurocrine Biosciences stock opened at $127.91 on Wednesday. The firm has a 50 day moving average of $118.83 and a 200 day moving average of $131.74. The firm has a market capitalization of $12.95 billion, a price-to-earnings ratio of 34.29 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12-month low of $110.52 and a 12-month high of $157.98.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.